Lexaria Bioscience ( (LEXX) ) has shared an announcement.
In 2024, Lexaria Bioscience Corp. made significant strides by focusing on GLP-1 drug delivery, achieving promising results from multiple human and animal studies, which highlight the potential of their DehydraTECH technology. The company successfully raised $13.4 million to support its operations and development plans, launched its first Phase 1b study in Australia, received FDA clearance for a hypertension study, and expanded its patent portfolio with eight new patents, reflecting its strengthened position in the pharmaceutical industry.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing primarily on developing oral-based drug delivery technologies. The company is leveraging its proprietary DehydraTECH technology to target the growing GLP-1 drug sector, which is one of the largest and fastest-growing in the world.
YTD Price Performance: -21.30%
Average Trading Volume: 198,671
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $30.01M
See more insights into LEXX stock on TipRanks’ Stock Analysis page.